Members Only Content

Subscribe to get full access

Free Preview

7investing Lead Advisor Dana Abramovitz’s recommendation for August 2022 is health care technology company that is a first mover in a new and growing market.


Drug development is complex, time consuming, and costly, and there is no guarantee that the drug candidate will make it through the process to commercialization.


7investing Lead Advisor Dana Abramovitz’s recommendation for August 2022 is a relatively young company that is disrupting drug development and working to create a new and growing market for therapeutics. The company already has three therapeutics on the market and has over a dozen more in its development pipeline. It saw triple digit growth YoY and is setting itself up to continue that growth as the market evolves.

Transcript

The health care industry is hard to disrupt. Medical schools care out the same traditions they’ve been using for hundreds of years, doctors use the same instruments, and the industry just seems resistant to change.

Hi, I’m Dana Abramovitz, 7investing Lead Advisor. We’re here to empower you to invest in your future by giving you our seven best stock recommendations every month.

My recommendation this month is a health technology company that is working to disrupt the health care industry and is actually succeeding. It is a first mover in a new and growing market and has multiple therapies on the market with a dozen more in its pipeline. It has seen triple digit growth year over year and it is setting itself up to continue growing.

To learn more about all seven stock recommendations this month, including mine, please visit 7investing.com/subscribe or click the link at the end of this video. We’re 7investing. We’re here to empower you to invest in your future.

related news & insights

  • 7investing logo next to the Upstart logo.
    June 12, 2025||0 min||||

    Upstart Deep Dive: June 2025

    Upstart Recommendation Report Upstart Presentation Slides

  • May 30, 2025||0.8 min||||

    7investing Exclusive: A Deep Dive Into Lemonade

    Lemonade (NYSE: LMND) is a new player who's really adding zest to the insurance industry. Its AI-powered underwriting enables it to [...]

  • May 16, 2025||46.1 min||||

    What’s Next for Digital Advertising? 7investing Interviews PubMatic CEO Rajeev Goel

    PubMatic just reported first quarter 2025 results. Aside from the headwinds of a DSP partner changing its bidding process, the [...]